0001661053 2026-01-01 2026-06-30 0001661053 2026-07-28 0001661053 2026-06-30 0001661053 2025-12-31 0001661053 2026-04-01 2026-06-30 0001661053 2025-04-01 2025-06-30 0001661053 2025-01-01 2025-06-30 0001661053 us-gaap:CommonStockMember 2026-03-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001661053 us-gaap:RetainedEarningsMember 2026-03-31 0001661053 2026-03-31 0001661053 us-gaap:CommonStockMember 2025-03-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001661053 us-gaap:RetainedEarningsMember 2025-03-31 0001661053 2025-03-31 0001661053 us-gaap:CommonStockMember 2025-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001661053 us-gaap:RetainedEarningsMember 2025-12-31 0001661053 us-gaap:CommonStockMember 2024-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001661053 us-gaap:RetainedEarningsMember 2024-12-31 0001661053 2024-12-31 0001661053 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001661053 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001661053 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001661053 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001661053 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001661053 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001661053 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001661053 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001661053 us-gaap:CommonStockMember 2026-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001661053 us-gaap:RetainedEarningsMember 2026-06-30 0001661053 us-gaap:CommonStockMember 2025-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001661053 us-gaap:RetainedEarningsMember 2025-06-30 0001661053 2025-06-30 0001661053 NVNO:BoardOfDirectorsMember 2026-01-02 2026-01-02 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2026-06-30 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentDebtSecuritiesMember 2025-12-31 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member NVNO:InsuredMoneyMarketAccountMember 2026-06-30 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member NVNO:InsuredMoneyMarketAccountMember 2025-12-31 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2026-06-30 0001661053 us-gaap:DebtSecuritiesMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0001661053 us-gaap:EmployeeStockOptionMember 2026-04-01 2026-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2026-06-30 0001661053 us-gaap:WarrantMember 2026-04-01 2026-06-30 0001661053 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001661053 us-gaap:WarrantMember 2025-04-01 2025-06-30 0001661053 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001661053 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001661053 us-gaap:WarrantMember 2025-01-01 2025-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-06-30 0001661053 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0001661053 NVNO:EmployeeExpenseMember 2026-04-01 2026-06-30 0001661053 NVNO:EmployeeExpenseMember 2025-04-01 2025-06-30 0001661053 NVNO:EmployeeExpenseMember 2026-01-01 2026-06-30 0001661053 NVNO:EmployeeExpenseMember 2025-01-01 2025-06-30 0001661053 NVNO:ClinicalMember 2026-04-01 2026-06-30 0001661053 NVNO:ClinicalMember 2025-04-01 2025-06-30 0001661053 NVNO:ClinicalMember 2026-01-01 2026-06-30 0001661053 NVNO:ClinicalMember 2025-01-01 2025-06-30 0001661053 NVNO:ProductsMember 2026-04-01 2026-06-30 0001661053 NVNO:ProductsMember 2025-04-01 2025-06-30 0001661053 NVNO:ProductsMember 2026-01-01 2026-06-30 0001661053 NVNO:ProductsMember 2025-01-01 2025-06-30 0001661053 NVNO:OtherMember 2026-04-01 2026-06-30 0001661053 NVNO:OtherMember 2025-04-01 2025-06-30 0001661053 NVNO:OtherMember 2026-01-01 2026-06-30 0001661053 NVNO:OtherMember 2025-01-01 2025-06-30 0001661053 NVNO:ProfessionalFeesMember 2026-04-01 2026-06-30 0001661053 NVNO:ProfessionalFeesMember 2025-04-01 2025-06-30 0001661053 NVNO:ProfessionalFeesMember 2026-01-01 2026-06-30 0001661053 NVNO:ProfessionalFeesMember 2025-01-01 2025-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2026-04-01 2026-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2025-04-01 2025-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2026-01-01 2026-06-30 0001661053 NVNO:ReserveForUncollectiblePrepaidClinicalCostsMember 2025-01-01 2025-06-30 0001661053 NVNO:OccupanciesMember 2026-04-01 2026-06-30 0001661053 NVNO:OccupanciesMember 2025-04-01 2025-06-30 0001661053 NVNO:OccupanciesMember 2026-01-01 2026-06-30 0001661053 NVNO:OccupanciesMember 2025-01-01 2025-06-30 0001661053 NVNO:InsuranceMember 2026-04-01 2026-06-30 0001661053 NVNO:InsuranceMember 2025-04-01 2025-06-30 0001661053 NVNO:InsuranceMember 2026-01-01 2026-06-30 0001661053 NVNO:InsuranceMember 2025-01-01 2025-06-30 iso4217:USD shares iso4217:USD shares NVNO:Integer false --12-31 Q2 0001661053

10-Q true 2026-06-30 2026 false 001-38325 enVVeno Medical Corporation DE 33-0936180 70 Doppler Irvine CA 92618 (949) 261-2900 Common Stock, $0.00001 par value NASDAQ NVNO Yes Yes Non-accelerated Filer true false false 682722

2841000

3065000

18645000

25147000

596000

614000

22082000

28826000

78000

51000

469000

654000

31000 31000

22660000

29562000

1485000

1732000

402000

390000

1887000

2122000

103000

310000

1990000

2432000

0.00001

10000000

0.00001

250000000

673000

656000

199446000

198457000

-178776000

-171327000

20670000

27130000

22660000

29562000

2076000

2891000

4187000

5448000

1720000

4158000

3671000

6555000

-3796000

-7049000

-7858000

-12003000

209000

239000

447000

665000

-22000

-79000

-65000

-273000

9000

195000

31000

414000

-4000

196000

355000

409000

806000

-3600000

-6694000

-7449000

-11197000

-5.37

-11.52

-11.18

-19.27

671000

581000

666000

581000

656000

198923000

-175176000

23747000

17000

126000

397000

-3600000

673000

199446000

-178776000

20670000

501000

194665000

-156358000

38307000

49000

1444000

-6694000

550000

196109000

-163052000

33057000

656000

198457000

-171327000

27130000

17000

126000

-1000

864000

-7449000

673000

199446000

-178776000

20670000

501000

194014000

-151855000

42159000

501000

194014000

-151855000

42159000

2095000

49000

-11197000

550000

196109000

-163052000

33057000

550000

196109000

-163052000

33057000

-7449000

-11197000

864000

2095000

-32000 74000

-4000

185000

178000

-65000

-273000

-18000

-119000

-247000

907000

-195000

-182000

-6787000

-7733000

47253000

24835000

40816000

16807000

5000

6437000

8023000

126000

-224000

290000

3065000

1754000

2841000

2044000

<p id="xdx_804_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zmUEh45WSBKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 1 – Business Organization and Nature of Operations The Company enVVeno Medical Corporation (the “Company”) is a late-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing a replacement venous valve for patients suffering from severe Chronic Venous Insufficiency (“CVI”) of the deep venous system of the leg. The Company is focused on its next-generation, non-surgical replacement venous valve, called the enVVe® System. The enVVe System consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe Valve is a first-in-class transcatheter based replacement venous valve being developed for the treatment of severe, deep venous CVI. The enVVe Valve is designed to act as a one-way valve, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. In April 2026, the U.S. Food and Drug Administration (“FDA”) awarded the Company an Investigational Device Exemption (“IDE”) approval to proceed with a U.S. pivotal study of the enVVe System. The Transcatheter Venous Valve Endoprosthesis (“TAVVE”) pivotal study will evaluate the Company’s minimally invasive enVVe System for patients with severe CVI. The IDE approval positions the Company to advance what could become the first effective treatment option for the approximately 3 million U.S. patients who suffer from the debilitating impact of severe CVI due to malfunctioning valves in the deep veins of the leg. The first stage of the TAVVE® study, which is expected to commence in the second half of 2026, will consist of 10 patients, whose 30-day safety results will be submitted to the FDA for review. This group of 10 patients will continue to be followed as a separate cohort throughout the study, and their safety and efficacy data will be reported publicly from time to time. The second stage of the study, which will begin immediately after the 30-day safety results for the first group are reported to the FDA, will enroll 220 patients, with 165 patients receiving the enVVe valve, and 55 patients randomized into a control arm who will receive standard of care treatment. The results from the patients who receive the enVVe valve will be compared to the results from the patients in the control arm of the study. The TAVVE study will enroll patients at up to 40 U.S. clinical sites and will include vascular surgeons, interventional radiologists and interventional cardiologists. One year after the 220th patient is enrolled in the second stage of the study, the Company would be eligible to file for FDA post-marketing approval. 2026 Reverse Stock Split On January 2, 2026, the Company’s board of directors (the “Board”) approved a one-for-thirty-five (1:35) reverse stock split of the outstanding shares of our common stock (the “Reverse Stock Split”). On January 16, 2026, the Company filed an amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, which became effective on January 20, 2026. The amendment did not change the number of authorized shares of our common stock. Except as the context otherwise requires, all common stock share numbers, share price amounts (including exercise prices, conversion prices, and closing market prices) and shares issued upon the exercise of warrants contained in the unaudited condensed financial statements and notes hereto have been retroactively adjusted to reflect the Reverse Stock Split.

one-for-thirty-five (1:35)

Note 2 – Management’s Liquidity Plan As of June 30, 2026, the Company had a cash and investment balance of $21.5 million and working capital of $20.2 million. Although the Company expects to continue incurring losses for the foreseeable future and will need to raise additional capital to sustain its operations, pursue its product development initiatives and penetrate markets for the sale of its products, management believes that the Company’s capital resources are sufficient to meet its obligations as they become due within one year after the date of this Quarterly Report, and sustain operations.

21500000

20200000

Note 3 – Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, such statements include all adjustments (consisting of normal recurring items) which are considered necessary for a fair presentation of the Company’s unaudited condensed financial statements of the Company as of and for the three and six months ended June 30, 2026 and 2025, and as of December 31, 2025. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the operating results for the full year. These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2026. The accompanying condensed balance sheet as of December 31, 2025 has been derived from the Company’s audited financial statements.

Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, such statements include all adjustments (consisting of normal recurring items) which are considered necessary for a fair presentation of the Company’s unaudited condensed financial statements of the Company as of and for the three and six months ended June 30, 2026 and 2025, and as of December 31, 2025. The results of operations for the three and six months ended June 30, 2026 are not necessarily indicative of the operating results for the full year. These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 26, 2026. The accompanying condensed balance sheet as of December 31, 2025 has been derived from the Company’s audited financial statements.

<p id="xdx_80D_eus-gaap--InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_zWPCrxVYrGJd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Note 4 – Investments The components of investments were as follows: Schedule of Components of Investments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair Value Level 1</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. Government Securities</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z7QdrQbvxxqb" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Cash equivalents">1,402</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_znfxS03Qwe6b" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Short-term investments">18,645</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zYJB8TbIXohd" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Cash equivalents">626</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zsWEPXhAUpUd" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Short-term investments">25,147</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Insured Money Market Account</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zFqfH2p80wpa" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">757</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z1Zfv0ebQiog" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zvTBXIx1Xpoi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">1,713</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z6PGCakWhSTg" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total investments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zEZSXeIEwKM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash equivalents">2,159</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zxBMK8OqbJC5" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term investments">18,645</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z4HjHDQOFO4j" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash equivalents">2,339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zPwjikUFK6X9" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term investments">25,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Unrealized losses of $22,000 and $0.1 million for the three months ended June 30, 2026 and 2025, respectively, and $0.1 million and $0.3 million for the six months ended June 30, 2026 and 2025, respectively, are from fixed-income securities and are primarily attributable to changes in interest rates.

The components of investments were as follows: Schedule of Components of Investments <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Cash Equivalents</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Short-Term Investments</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Fair Value Level 1</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left; padding-bottom: 1pt">U.S. Government Securities</td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z7QdrQbvxxqb" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Cash equivalents">1,402</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_znfxS03Qwe6b" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Short-term investments">18,645</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zYJB8TbIXohd" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Cash equivalents">626</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__us-gaap--USGovernmentDebtSecuritiesMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zsWEPXhAUpUd" style="padding-bottom: 1pt; width: 10%; text-align: right" title="Short-term investments">25,147</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Insured Money Market Account</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zFqfH2p80wpa" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">757</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z1Zfv0ebQiog" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zvTBXIx1Xpoi" style="border-bottom: Black 1pt solid; text-align: right" title="Cash equivalents">1,713</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--InvestmentTypeAxis__custom--InsuredMoneyMarketAccountMember__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z6PGCakWhSTg" style="border-bottom: Black 1pt solid; text-align: right" title="Short-term investments">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total investments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zEZSXeIEwKM8" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash equivalents">2,159</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20260630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zxBMK8OqbJC5" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term investments">18,645</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_ecustom--CashEquivalentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_z4HjHDQOFO4j" style="border-bottom: Black 2.5pt double; text-align: right" title="Cash equivalents">2,339</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--InvestmentsFairValueDisclosure_iI_pn3n3_c20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByAssetClassAxis__us-gaap--DebtSecuritiesMember_zPwjikUFK6X9" style="border-bottom: Black 2.5pt double; text-align: right" title="Short-term investments">25,147</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1402000

18645000

626000

25147000

757000 1713000 2159000

18645000

2339000

25147000

22000

100000

300000

Note 5 – Concentrations The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000 at each institution. There were aggregate uninsured cash balances of $1.8 million and $1.1 million as of June 30, 2026 and December 31, 2025, respectively.

250000

1800000

1100000

<p id="xdx_800_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zJtGLQEOy62j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Note 6 – Accounts Payable Accrued Expenses and Other Current Liabilities <p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zvDsR3mHp9Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Accounts payable, accrued expenses and other current liabilities consist of the following: Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630_zefP3YqWRtm5" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_z3Olny2z98Da" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maALAOLzCZ3_zvjimftOYDu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">540</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">358</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pn3n3_maALAOLzCZ3_zDTAHANnHJue" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued compensation costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">679</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccruedClinicalCosts_iI_pn3n3_maALAOLzCZ3_zTJVsdukCxFl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued clinical costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">445</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedSeverance_iI_pn3n3_maALAOLzCZ3_z1FvROiCCrF2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued severance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALAOLzCZ3_ziqEWaDMPTtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">134</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtALAOLzCZ3_zf5FzMi9ML9e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable, accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,485</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zvDsR3mHp9Ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Accounts payable, accrued expenses and other current liabilities consist of the following: Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49D_20260630_zefP3YqWRtm5" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20251231_z3Olny2z98Da" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--AccountsPayableCurrent_iI_pn3n3_maALAOLzCZ3_zvjimftOYDu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">540</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">358</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--WorkersCompensationLiabilityCurrent_iI_pn3n3_maALAOLzCZ3_zDTAHANnHJue" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued compensation costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">441</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">679</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_ecustom--AccruedClinicalCosts_iI_pn3n3_maALAOLzCZ3_zTJVsdukCxFl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued clinical costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">392</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">445</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--AccruedSeverance_iI_pn3n3_maALAOLzCZ3_z1FvROiCCrF2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued severance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALAOLzCZ3_ziqEWaDMPTtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">112</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">134</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pn3n3_mtALAOLzCZ3_zf5FzMi9ML9e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable, accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,485</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,732</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

540000

358000

441000

679000

392000 445000 116000

112000

134000

1485000

1732000

Note 7 – Commitments and Contingencies Litigations Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.

Note 8 –Stockholders’ Equity Omnibus Incentive Plan Stock Options Stock-based compensation expense is reflected in selling, general and administrative expenses in the accompanying condensed statements of operations and was $0.4 million and $1.4 million during the three months ended June 30, 2026 and 2025, respectively, and $0.9 million and $2.1 million during the six months ended June 30, 2026 and 2025, respectively. As of June 30, 2026, there was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9mnEa8AXksa" title="Unrecognized stock-based compensation expense">1.7 million of unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over the weighted average remaining vesting period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zM9dPluyMrQf" title="Weighted average remaining vesting period">1.36 years. There were <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_do_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zollQgHaVS6j" title="Shares granted"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pn3n3_do_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zKsDYYkOCQn" title="Shares granted">no options granted during the three and six months ended June 30, 2026. There were 17,142 options granted during the three and six months ended June 30, 2025 in connection with entering into certain employment and consulting agreements. There were no options exercised during the three and six months ended June 30, 2026 and 2025. There were <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrb7eTeOGFj8" title="Shares forfeited">7,850 and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zz3e2kaVtgza" title="Shares forfeited">12,316 option grants forfeited during the three and six months ended June 30, 2026, respectively. There were <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zZ4OqUuf7RA6" title="Shares forfeited"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pn3n3_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXGn092Btwgd" title="Shares forfeited">15,110 option grants forfeited during the three and six months ended June 30, 2025. Warrants There were <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pn3n3_do_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0Yoei4ViTy1" title="Number of warrants, issued"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pn3n3_do_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUtMLpjMZiI3" title="Number of warrants, issued">no warrants issued or exercised during the three and six months ended June 30, 2026. Pre-funded warrants issued in 2023 and 2021 were exercised for 48,890 shares of common stock during the three and six months ended June 30, 2025 at an exercise price of $0.0001 per pre-funded warrant. There were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pn3n3_do_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKELj6NvYsra" title="Number of warrants, expired">no warrants that expired during the three months ended June 30, 2026. There were warrants exercisable for <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pn3n3_c20250401__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqUebl1oTl6c" title="Number of warrants, expired">11,128 shares of common stock that expired during the three months ended June 30, 2025. There were warrants exercisable for <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pn3n3_c20260101__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPqvFcu0Air8" title="Number of warrants, expired">85,219 and <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_pn3n3_c20250101__20250630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zI0HaGaJoxqk" title="Number of warrants, expired">11,390 shares of common stock that expired during the six months ended June 30, 2026 and 2025, respectively. Equity Issuances There were approximately 17,000 shares of common stock issued during the three and six months ended June 30, 2026 under our at-the-market equity program resulting in proceeds of $0.1 million, net of transaction fees.

400000

1400000

900000

2100000

1700000

P1Y4M9D

17142000

7850000

12316000

15110000

48890000 48890000

0.0001

11128000

85219000

11390000

17000

100000

Note 9 – Net Loss per Share <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEpNuP1kact1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share: Schedule of Dilutive Net Loss Per Common Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260101__20260630_zCn1CW6x2DNk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250630_zGO0g558QuL1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKqW7PzJGjU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares of common stock issuable upon exercise of warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">172</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">281</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zgOmDd8GDtrd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Shares of common stock issuable upon exercise of options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">174</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">180</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zGGYAqeANK71" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive common stock equivalents excluded from diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">346</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">461</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zEpNuP1kact1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share: Schedule of Dilutive Net Loss Per Common Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260101__20260630_zCn1CW6x2DNk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250630_zGO0g558QuL1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zKqW7PzJGjU3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Shares of common stock issuable upon exercise of warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">172</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">281</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zgOmDd8GDtrd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Shares of common stock issuable upon exercise of options</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">174</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">180</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_zGGYAqeANK71" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Potentially dilutive common stock equivalents excluded from diluted net loss per share</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">346</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">461</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

172000

281000

174000

180000

346000

461000

Note 10 – Segment Reporting The Company has determined that it currently operates in a 1single segment, Medical Device development, located in a single geographic location, the United States. The accounting policies of the segment are the same as those described in the summary of significant accounting policies set forth in the Company’s Form 10-K, filed with the SEC on March 26, 2026. Since the Company operates in a single segment, the measure of segment total assets and loss from operations is the same as that reported on the accompanying balance sheets as total assets, and the accompanying statement of operations as loss from operations, respectively. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM uses operating expenses to measure performance against progress in its clinical trials and its product development. The following table sets forth segment expenses. <p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z4JxZ7UerZwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Schedule of Segment Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260401__20260630_z48vthboM3H6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250401__20250630_zzioR6IBG1f8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260101__20260630_zR0EcpmUBthg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250101__20250630_z64LSGPrXRQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Research and Development:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zA3u4Cod62hk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Employee expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,329</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,699</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalMember_zBIQfxf4mfAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Clinical</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,832</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProductsMember_zRyFwHxFJN5d" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Product</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">548</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zFV0czLXdbji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">83</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">199</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">136</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">369</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_msOILzwMI_zQiuUKdwfn7j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,076</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,891</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,187</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,448</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Selling, General and Administrative Expense:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zfcHskCGkcia" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Employee expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,544</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProfessionalFeesMember_zmTi1nwqcOGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">749</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">888</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ReserveForUncollectiblePrepaidClinicalCostsMember_zotVsGfgG5dg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reserve for uncollectible prepaid clinical costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OccupanciesMember_zbDkYSLRYsWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Occupancy</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">158</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">319</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--InsuranceMember_z6COFKFW7J45" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">320</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zDEqXfheAAoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">157</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">606</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">353</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">863</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_msOILzwMI_zWOR2ahhIgZh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total selling, general and administrative expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,158</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,671</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,555</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILzwMI_maNILzmHo_zlqiDWaDzDPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Loss from Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,003</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_iN_pn3n3_di_maNILzmHo_zBe8yqKHP7ve" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Adjustments and reconciling items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(196</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(355</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(409</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(806</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzmHo_zGS5ZJaW3qMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,694</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,197</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Adjustments and reconciling items between loss from operations and net loss consist of interest income and realized and unrealized gains and losses related to the Company’s investments in U.S. Treasury securities.

<p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z4JxZ7UerZwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Schedule of Segment Expenses <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260401__20260630_z48vthboM3H6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250401__20250630_zzioR6IBG1f8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260101__20260630_zR0EcpmUBthg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20250101__20250630_z64LSGPrXRQ9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Six Months Ended June 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Research and Development:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zA3u4Cod62hk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 36%; text-align: left">Employee expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,211</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">1,329</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,347</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,699</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ClinicalMember_zBIQfxf4mfAa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Clinical</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,832</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProductsMember_zRyFwHxFJN5d" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Product</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">112</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">548</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zFV0czLXdbji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">83</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">199</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">136</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">369</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--ResearchAndDevelopmentExpense_pn3n3_msOILzwMI_zQiuUKdwfn7j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total research and development</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,076</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,891</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,187</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">5,448</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Selling, General and Administrative Expense:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--EmployeeExpenseMember_zfcHskCGkcia" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Employee expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">897</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,310</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,960</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,544</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ProfessionalFeesMember_zmTi1nwqcOGa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">362</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">308</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">749</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">888</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--ReserveForUncollectiblePrepaidClinicalCostsMember_zotVsGfgG5dg" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Reserve for uncollectible prepaid clinical costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">626</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OccupanciesMember_zbDkYSLRYsWa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Occupancy</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">158</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">151</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">319</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">314</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--InsuranceMember_z6COFKFW7J45" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">146</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">157</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">290</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">320</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_hus-gaap--StatementBusinessSegmentsAxis__custom--OtherMember_zDEqXfheAAoa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">157</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">606</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">353</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">863</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SellingGeneralAndAdministrativeExpense_pn3n3_msOILzwMI_zWOR2ahhIgZh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total selling, general and administrative expense</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,720</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4,158</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,671</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,555</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iNT_pn3n3_di_mtOILzwMI_maNILzmHo_zlqiDWaDzDPc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Loss from Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,858</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,003</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpense_iN_pn3n3_di_maNILzmHo_zBe8yqKHP7ve" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Adjustments and reconciling items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(196</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(355</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(409</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(806</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--NetIncomeLoss_iNT_pn3n3_di_mtNILzmHo_zGS5ZJaW3qMg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,600</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,694</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,449</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">11,197</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1211000

1329000

2347000

2699000

670000

960000

1514000

1832000

112000

403000

190000

548000

83000

199000

136000

369000

2076000

2891000

4187000

5448000

897000

2310000

1960000

3544000

362000

308000

749000

888000

626000

158000

151000

319000

314000

146000

157000

290000

320000

157000

606000

353000

863000

1720000

4158000

3671000

6555000

-3796000

-7049000

-7858000

-12003000

196000

355000

409000

806000

-3600000

-6694000

-7449000

-11197000